New FDA Approval Offers long-Term Relief for Chronic Hand Eczema, Shifting Treatment Paradigm
WASHINGTON D.C. – for the first time, individuals battling chronic hand eczema have access to a steroid-free treatment option rigorously studied and specifically approved for their condition, following the July 23 approval of delgocitinib (Anzupgo; LEO Pharma). This landmark decision by the FDA signals a notable shift in how dermatologists approach a disease historically managed with therapies carrying substantial long-term risks.
Chronic hand eczema impacts millions, causing debilitating itch, pain, and skin damage that significantly diminishes quality of life.Existing treatments, primarily topical corticosteroids, are effective for short-term flare-ups but are not designed for continuous use due to potential cutaneous and systemic side effects. The approval of delgocitinib addresses a critical unmet need, offering a durable and safer alternative for long-term management. “The most significant implication of an approved therapy in this disease state is the fact that No. 1, chronic hand eczema is recognized as a burdensome disease worthy of individual regulatory approval,” explained Raj Chovatiya, MD, PhD, MSCI.”No. 2, the fact that patients now have something that’s been rigorously studied and tested in patients that have chronic hand eczema.And [No.] 3, the product shows considerable efficacy and safety, which give it advantages over topical corticosteroids.”
Delgocitinib, distinguished by its novel mechanism of action, provides a considerable advantage over customary treatments. Dr. Chovatiya emphasized the change in the treatment paradigm, stating, “if [corticosteroids are] not enough to really help resolve the signs and symptoms of disease in the short term, I have a much safer and more effective long-term treatment in the case of topical delgocitinib. Really night and day in terms of our treatment approach.”
While corticosteroids may still play a role in short-term relief, the availability of delgocitinib offers patients a therapy combining safety, efficacy, and durability – without the drawbacks associated with prolonged steroid use. This development represents a pivotal moment in the care of chronic hand eczema, offering renewed hope for lasting relief.
